ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 6 of 60
Up
УЖМБС 2019, 4(6): 46–51
https://doi.org/10.26693/jmbs04.06.046
Experimental Medicine and Morphology

Influence of Toxic and Subtoxic Doses of Diclofenac Sodium on Mechanisms of Differentiation of Granulocytary Row Cells, Undifferentiated Blasts and Mitotic Cells in the Bone Marrow of Rats

Ivanov O. S. 1, Bagmut I. Yu. 2, Tsapko G. V. 3, Sklyar S. I. 1
Abstract

In humans and animals, the hematopoietic system is a diverse group of cells whose task is to maintain the internal environment of the body. Among all non-steroidal anti-inflammatory drugs, the leading place belongs to sodium Diclofenac, which is the first-line drug in the treatment of inflammatory diseases and pain relief, including after surgical interventions. It is often prescribed in short courses, however, in some cases, the disease is treated by it for many years. The purpose of this work was to determine the effect of the drug Diclofenac sodium on myelocytic cells, undifferentiated blasts and the process of mitosis of myeloid cells within a short course for 4 days and to compare the results with the control group. Material and methods. The studies were conducted on white outbred rats in the amount of 48 individuals, the bone marrow of which was removed from the femur after decapitation. Animals of the control group received an oral physiological solution of sodium chloride according to the method and mode of administration of the test substances to animals of the main group. The study of the obtained material was carried out microscopically and using Goryaev camera. Results and discussion. During the experiment, a negative effect of toxic doses of the drug on the bone marrow and morphology of the studied cells was established, primarily a sharp decrease in their number. The morphological structure violation was also observed in the studied group of cells. On the contrary, the use of a subtoxic dose of the drug contributed to an increase in the production of new cells of the studied series of bone marrow, most likely due to activation of the body immune system. The rat bone mass was reduced when using a toxic dose, which was not observed in animals of the control group. In the treatment of diseases, the short courses are optimal for the toxic doses of Diclofenac sodium in order to increase the number of rat granulocyte cells in the rat bone marrow and the body immune system. When using a toxic dose of the drug, there was a decrease in the number of cells of the myelocytic series of the studied bone marrow of rats and its mass in comparison with the control group. Conclusion. Thus, it makes sense to recommend the use of subtoxic doses of Diclofenac sodium in order to increase the level of the immune system and the level of cells of the myelocytic number of the red brain in clinical practice. The prospect of further research is to determine the number and morphology of other red bone marrow cells in rats and inflammation factors under the influence of short-term administration of the drug Diclofenac sodium in rats and the implementation of the results into clinical practice.

Keywords: bone marrow, Diclofenac sodium, myelocytes, undifferentiated blasts, toxic effect

Full text: PDF (Ukr) 442K

References
  1. Danylova YG, Yushkov BG, Ulytko MV. Vlyyanye systemy fagotsytyruyushchykh mononuklearov na erytropoez v erytroblastycheskykh ostrovkakh kostnogo mozga [The influence of the system of phagocytic mononuclear cells on erythropoiesis in erythroblastic islets of the bone marrow]. Med ymmunologyya. 2006; 8(2/3): 135. [Russian]
  2. Leontyuk AS, Sluka BA. Osnovy vozrastnoy gystologyy [The basics of age-related histology]. Mynsk: Vysheyshaya shkola; 2000. 418 p. [Russian]
  3. Deryvedmid LV, Vereitynova VP. Kombinovani khondroprotektory pry likuvanni osteoartrytu [Combined chondroprotective treatment for treating osteoarthritis]. Bil, sugloby, khrebet. 2018; 8(1): 31–6. [Ukrainian]
  4. Gryshchenko VA. Gematologichnyy profil u shchuriv pry eksperymentalnomu dyklofenak–indukovanomu gepatyti [Hematologic profile in schuria with experimental diclofenac–induced hepatitis]. Ukrainian Journal of Ecology. 2017; 7(3): 78–83. [Ukrainian] https://doi.org/10.15421/2017_52
  5. Selyuk MN, Kozachok NN, Selyuk OV. Novye grany klassycheskogo nesteroydnogo protyvovospalytelnogo sredstva dyklofenak [New facets of the classic non-steroidal anti-inflammatory drug diclofenac]. Suchasni preparaty ta tekhnologiyi. 2013; 8(104): 35–40. [Russian]
  6. Karateev AE, Nasonov EL, Yakhno NN. Ratsyonalnoe prymenenye nesteroydnykh protyvovospalytelnykh preparatov (NPVP) v klynycheskoy praktyke [Rational use of non-steroidal anti-inflammatory drugs (NSAIDs) in clinical practice]. Sovremennaya revmatologyya. 2015; 1(15): 7–23. [Russian]
  7. Karateev AE. NPVP–Gastropatyya: Dynamyka za 12 let [NSAIDs–Gastropathy: Dynamics over 12 years]. Nauchno–praktycheskaya revmatologyya. 2011; 3: 20–4. [Russian] https://doi.org/10.14412/1995-4484-2011-568
  8. Karateev AE, Nasonov EL, Yvashkyn VT. Ratsyonalnoe yspolzovanye nesteroydnykh protyvovospalytelnykh preparatov. Klynycheskye rekomendatsyy [The rational use of non-steroidal anti-inflammatory drugs. Clinical recommendations]. Nauchno–praktycheskaya revmatologyya. 2018; 56(1): 1–29. [Russian]
  9. Kozachok NN, Selyuk MM, Bychkova SA, Bychkova NG. Nesteroydnye protyvovospalytelnye preparaty – kto lydyruet v sovremennoy klynyke? [Non-steroidal anti-inflammatory drugs – who leads in a modern clinic?]. Novosty medytsyny y farmatsyy. 2008; 4(235). [Russian]
  10. Volkova OV, Eletskyy YuK. Osnovy gystologyy s gystologycheskoy tekhnykoy [Basics of histology with a histological technique]. M: Medytsyna; 1971. 415 p. [Russian]
  11. Miyamoto G, Zahid N, Uetrecht JP. Oxidation of diclofenac to reactive intermediates by neutrophils, myeloperoxidase, and hypochlorous acid. Chem Res Toxicol. 1997; 10(4): 414–9. https://www.ncbi.nlm.nih.gov/pubmed/9114978. https://doi.org/10.1021/tx960190k